Do analysts prefer RDHL or ADIL?

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is RDHL or ADIL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Adial Pharmaceuticals N/A -203.87% -512.41%

Do analysts prefer CABR or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CABR or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A -1,153.12% -322.63% Redhill Biopharma N/A N/A N/A

Does the media refer more to CABR or RDHL?

In the previous week, Redhill Biopharma had 6 more articles in the media than Caring Brands. MarketBeat recorded 8 mentions for Redhill Biopharma and 2 mentions for Caring Brands. Caring Brands' average media sentiment score of 0.83 beat Redhill Biopharma's score of 0.00 indicating that Caring Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caring Brands 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDHL or DARE?

Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor RDHL or DARE?

In the previous week, Redhill Biopharma had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 8 mentions for Redhill Biopharma and 3 mentions for Dare Bioscience. Redhill Biopharma's average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate KPRX or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KPRX or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Redhill Biopharma N/A N/A N/A

Do analysts prefer RDHL or MBRX?

Moleculin Biotech has a consensus price target of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is RDHL or MBRX more profitable?

Redhill Biopharma's return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Moleculin Biotech N/A -143.51% -24.53%

Does the media favor RDHL or MBRX?

In the previous week, Redhill Biopharma and Redhill Biopharma both had 8 articles in the media. Moleculin Biotech's average media sentiment score of 0.11 beat Redhill Biopharma's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Redhill Biopharma (RDHL) Competitors

$0.71 -0.03 (-3.81%)

As of 09/3/2026 04:00 PM Eastern

Compare

RDHL vs. ADIL, CABR, DARE, KPRX, and MBRX

Should you buy Redhill Biopharma stock or one of its competitors? Redhill Biopharma's main competitors and comparable companies include Adial Pharmaceuticals (ADIL), Caring Brands (CABR), Dare Bioscience (DARE), Kiora Pharmaceuticals (KPRX), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Redhill Biopharma compare to Adial Pharmaceuticals?

Redhill Biopharma (NASDAQ:RDHL) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Redhill Biopharma's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Redhill Biopharma has higher revenue and earnings than Adial Pharmaceuticals. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.94	-$430K	$900.00	0.00
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

In the previous week, Redhill Biopharma had 8 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 8 mentions for Redhill Biopharma and 0 mentions for Adial Pharmaceuticals. Redhill Biopharma's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Adial Pharmaceuticals	Neutral

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Summary

Redhill Biopharma beats Adial Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Redhill Biopharma compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Redhill Biopharma had 6 more articles in the media than Caring Brands. MarketBeat recorded 8 mentions for Redhill Biopharma and 2 mentions for Caring Brands. Caring Brands' average media sentiment score of 0.83 beat Redhill Biopharma's score of 0.00 indicating that Caring Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caring Brands	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Caring Brands. Caring Brands is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A
Redhill Biopharma	$290K	14.94	-$430K	$900.00	0.00

7.2% of Redhill Biopharma shares are owned by institutional investors. 14.6% of Caring Brands shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-1,153.12%	-322.63%
Redhill Biopharma	N/A	N/A	N/A

Summary

Redhill Biopharma beats Caring Brands on 8 of the 10 factors compared between the two stocks.

How does Redhill Biopharma compare to Dare Bioscience?

Redhill Biopharma (NASDAQ:RDHL) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Redhill Biopharma has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.94	-$430K	$900.00	0.00
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A

Redhill Biopharma has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Redhill Biopharma's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Dare Bioscience	-803.80%	-748.30%	-38.75%

In the previous week, Redhill Biopharma had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 8 mentions for Redhill Biopharma and 3 mentions for Dare Bioscience. Redhill Biopharma's average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Redhill Biopharma has a beta of 4.96, indicating that its share price is 396% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

Summary

Redhill Biopharma beats Dare Bioscience on 12 of the 16 factors compared between the two stocks.

How does Redhill Biopharma compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Kiora Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, indicating that its share price is 396% more volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Redhill Biopharma's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Redhill Biopharma	N/A	N/A	N/A

In the previous week, Redhill Biopharma had 8 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 8 mentions for Redhill Biopharma and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Redhill Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has lower revenue, but higher earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A
Redhill Biopharma	$290K	14.94	-$430K	$900.00	0.00

Summary

Redhill Biopharma beats Kiora Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Moleculin Biotech?

Redhill Biopharma (NASDAQ:RDHL) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Redhill Biopharma and Redhill Biopharma both had 8 articles in the media. Moleculin Biotech's average media sentiment score of 0.11 beat Redhill Biopharma's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.94	-$430K	$900.00	0.00
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Moleculin Biotech has a consensus price target of $3.00, indicating a potential upside of 344.12%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Redhill Biopharma's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Moleculin Biotech	N/A	-143.51%	-24.53%

Summary

Redhill Biopharma beats Moleculin Biotech on 7 of the 13 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.51M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.28	25.38
Price / Sales	14.94	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.86	12.33	12.89	6.14
Net Income	-$430K	$2.82B	$3.47B	$349.01M
7 Day Performance	7.84%	2.60%	0.61%	-0.27%
1 Month Performance	10.02%	6.96%	5.73%	0.68%
1 Year Performance	-42.05%	9.48%	25.37%	14.84%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.1489 of 5 stars	$0.71 -3.8%	N/A	-44.3%	$4.51M	$290K	0.00	210
ADIL Adial Pharmaceuticals	2.7775 of 5 stars	$5.82 +7.8%	$15.63 +168.5%	-28.8%	$14.18M	N/A	N/A	20
CABR Caring Brands	0.4401 of 5 stars	$1.29 -4.8%	N/A	N/A	$14M	N/A	N/A	4	Gap Down
DARE Dare Bioscience	2.1423 of 5 stars	$0.82 +2.4%	$10.00 +1,118.5%	-65.4%	$12.26M	$1.03M	N/A	30
KPRX Kiora Pharmaceuticals	0.7705 of 5 stars	$2.59 -5.8%	$10.00 +286.1%	-8.9%	$12.17M	$16.02M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. ADIL, CABR, DARE, KPRX, and MBRX

How does Redhill Biopharma compare to Adial Pharmaceuticals?

Summary

How does Redhill Biopharma compare to Caring Brands?

Summary

How does Redhill Biopharma compare to Dare Bioscience?

Summary

How does Redhill Biopharma compare to Kiora Pharmaceuticals?

Summary

How does Redhill Biopharma compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. ADIL, CABR, DARE, KPRX, and MBRX

How does Redhill Biopharma compare to Adial Pharmaceuticals?

Is RDHL or ADIL more profitable?

Which has better earnings & valuation, RDHL or ADIL?

Does the media favor RDHL or ADIL?

Do analysts prefer RDHL or ADIL?

Do insiders & institutionals believe in RDHL or ADIL?

Which has more volatility & risk, RDHL or ADIL?

Summary

How does Redhill Biopharma compare to Caring Brands?

Does the media refer more to CABR or RDHL?

Do analysts prefer CABR or RDHL?

Which has preferable valuation and earnings, CABR or RDHL?

Do insiders & institutionals hold more shares of CABR or RDHL?

Is CABR or RDHL more profitable?

Summary

How does Redhill Biopharma compare to Dare Bioscience?

Do analysts recommend RDHL or DARE?

Do institutionals and insiders have more ownership in RDHL or DARE?

Which has stronger earnings & valuation, RDHL or DARE?

Is RDHL or DARE more profitable?

Does the media favor RDHL or DARE?

Which has more risk & volatility, RDHL or DARE?

Summary

How does Redhill Biopharma compare to Kiora Pharmaceuticals?

Which has more volatility & risk, KPRX or RDHL?

Do insiders & institutionals have more ownership in KPRX or RDHL?

Is KPRX or RDHL more profitable?

Does the media refer more to KPRX or RDHL?

Do analysts rate KPRX or RDHL?

Which has preferable earnings & valuation, KPRX or RDHL?

Summary

How does Redhill Biopharma compare to Moleculin Biotech?

Does the media favor RDHL or MBRX?

Which has more risk and volatility, RDHL or MBRX?

Which has higher earnings & valuation, RDHL or MBRX?

Do insiders & institutionals believe in RDHL or MBRX?

Do analysts prefer RDHL or MBRX?

Is RDHL or MBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools